NASDAQ:BNTX BioNTech (BNTX) Stock Price, News & Analysis $95.90 +3.84 (+4.17%) As of 10:17 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About BioNTech Stock (NASDAQ:BNTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioNTech alerts:Sign Up Key Stats Today's Range$92.30▼$96.0450-Day Range$90.58▼$116.5752-Week Range$79.52▼$124.00Volume179,883 shsAverage Volume1.08 million shsMarket Capitalization$24.25 billionP/E RatioN/ADividend YieldN/APrice Target$125.69Consensus RatingModerate Buy Company Overview BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics. BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world. BioNTech continues to advance vaccine programs targeting infectious diseases while expanding its oncology pipeline. Founded in 2008 by Uğur Şahin, Özlem Türeci, and Christoph Huber, BioNTech operates research and development activities in Europe, North America, and other international markets. Şahin serves as chief executive officer, while Türeci is the company’s chief medical officer. The company’s cancer programs include personalized immunotherapies designed to target tumor-specific characteristics.AI Generated. May Contain Errors. Read More BioNTech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreBNTX MarketRank™: BioNTech scored higher than 82% of companies evaluated by MarketBeat, and ranked 90th out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingBioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.65, and is based on 1 strong buy rating, 12 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialBioNTech has a consensus price target of $125.69, representing about 36.5% upside from its current price of $92.06.Amount of Analyst CoverageBioNTech has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioNTech's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioNTech are expected to grow in the coming year, from ($6.37) to ($5.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is -11.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is -11.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BioNTech's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.14% of the float of BioNTech has been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 2.59, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioNTech has recently increased by 0.86%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth.Read more about BioNTech's dividend. News and Social Media3.4 / 5News Sentiment0.46 News SentimentBioNTech has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 23 news articles for BioNTech this week, compared to 8 articles on an average week.Search Interest14 people have searched for BNTX on MarketBeat in the last 30 days. This is an increase of 8% compared to the previous 30 days.MarketBeat Follows2 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,301,215.00 in company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions15.52% of the stock of BioNTech is held by institutions.Read more about BioNTech's insider trading history. Receive BNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BNTX Stock News HeadlinesBioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 24,000 SharesOctober 9 at 4:11 AM | americanbankingnews.comBioNTech (NASDAQ:BNTX) CEO Sells 24,000 Shares of Company StockOctober 8 at 5:52 AM | insidertrades.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 9 at 1:00 AM | Investors Alley (Ad)BioNTech (NASDAQ: BNTX) CEO sells 93,000 shares under preplanned dealOctober 8 at 3:03 AM | americanbankingnews.comIs BioNTech (NasdaqGS:BNTX) Overvalued As Sales Face A Reset?October 7 at 10:13 PM | finance.yahoo.comBioNTech (NASDAQ:BNTX) CEO Sells $2,033,010.00 in StockOctober 7 at 5:07 AM | insidertrades.comBioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 17,000 Shares of Company StockOctober 3, 2026 | insidertrades.comBioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 27,000 SharesSeptember 29, 2026 | insidertrades.comSee More Headlines BNTX Stock Analysis - Frequently Asked Questions How have BNTX shares performed this year? BioNTech's stock was trading at $95.20 at the beginning of 2026. Since then, BNTX shares have decreased by 3.3% and is now trading at $92.06. How were BioNTech's earnings last quarter? BioNTech SE Sponsored ADR (NASDAQ:BNTX) announced its quarterly earnings data on Tuesday, August, 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by $0.14. The firm's revenue for the quarter was down 59.5% compared to the same quarter last year. Read the conference call transcript. How will BioNTech's stock buyback program work? BioNTech's board authorized a stock buyback plan on Thursday, May 7th 2026, which authorizes the company to buy back $1,000,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 4.2% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's board of directors believes its stock is undervalued. Does BioNTech have any subsidiaries? BioNTech subsidiaries include Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and others. When did BioNTech IPO? BioNTech (BNTX) raised $155 million in an IPO on Thursday, October 10th 2019. The company issued 10,000,000 shares at a price of $15.00-$16.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. Who are BioNTech's major shareholders? BioNTech's top institutional investors include Crocodile Capital Partners GmbH (0.01%), Quintet Private Bank Europe S.A. and Farther Finance Advisors LLC. Insiders that own company stock include Sierk Poetting and Ugur Sahin. View institutional ownership trends. How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/04/2026Today10/09/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BNTX's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BNTX CIK1776985 Webwww.biontech.com Phone49-61-31908-40Fax49-6131-908-4390Employees7,807Year Founded2008Price Target and Rating Average Price Target for BioNTech$125.69 High Price Target$155.00 Low Price Target$94.00 Potential Upside/Downside+30.4%Consensus RatingModerate Buy Rating Score (0-4)2.65 Research Coverage20 Analysts Profitability EPS (Trailing Twelve Months)($7.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.29 billion Net Margins-63.54% Pretax Margin-62.27% Return on Equity-6.86% Return on Assets-6.00% Debt Debt-to-Equity Ratio0.01 Current Ratio7.85 Quick Ratio7.80 Sales & Book Value Annual Sales$2.65 billion Price / Sales9.20 Cash Flow$1.35 per share Price / Cash Flow71.34 Book Value$96.59 per share Price / Book1.00Miscellaneous Outstanding Shares252,884,000Free Float204,330,000Market Cap$24.38 billion OptionableOptionable Beta1.25 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:BNTX) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNTech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
